ClinicalTrials.gg
RecruitingNCT07753850RECEPTIVE-CD1Updated Nov 12, 2026

A Study of SL-325 in Crohn's Disease Patients

A Phase 2 interventional study of SL-325 and Placebo in Crohn's Disease, sponsored by Shattuck Labs, Inc.. Recruiting at 20 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Shattuck Labs, Inc. · Phase 2, Interventional, and Treatment

How we know

Updated Nov 12, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Planned enrollment
117th of 528
232 · median 60
Started
2026
with 33 others
Phase 2
141 of 660
23 open now
Primary completion
2028-07
later than 104 of 162 live
Registered
655th of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 117th largest by planned enrollment of the 528 interventional ones that give a count, is one of 34 that started in 2026, is one of 141 in phase 2, reaches primary completion later than 104 of the 162 other live ones, and was the 655th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

116 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with moderate to severely active Crohn's disease.

The study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • A diagnosis of Crohn's disease confirmed by endoscopy and histopathology ≥ 3 months prior to Screening
  • Moderately to severely active CD as defined by CDAI of ≥ 220 and ≤ 450
  • SES-CD score ≥ 6 if ileocolonic or colonic disease, or ≥ 4 if isolated ileal disease, as assessed by central review
  • Demonstrated inadequate response, loss of response, or intolerance to one or more of the following Crohn's disease treatments: , immunomodulators, or an approved anti-tumor necrosis factor (TNF), anti-integrin, anti-interleukin (IL)-12/23, anti-interleukin (IL)-23p19, or Janus kinase inhibitor (JAK)

Key Exclusion Criteria:

  • Diagnosis of UC, indeterminate colitis, or any other gastrointestinal condition that could undermine the diagnosis of CD
  • CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and/or ileal involvement
  • Presence or suspicion of any of the following CD complications: intra-abdominal or perianal abscess; symptomatic stricture or colonic stenosis not passable in ileocolonoscopy, fistula, except for perianal fistula; active toxic megacolon or fulminant colitis; short bowel syndrome
  • Surgical bowel resection within 3 months before Screening, ≥ 3 bowel resections, or previous ileo-colonic resection of > 2 segments
  • Diagnosis of primary sclerosing cholangitis
  • Has a stoma, ileostomy, or colostomy.
  • Has prior or current gastrointestinal dysplasia, other than a completely removed low-grade dysplastic lesion.
  • Has active tuberculosis (TB) or inadequately treated latent tuberculosis (LTBI)
  • Prior exposure to any anti-DR3 or anti-TL1A agent or agent with an anti-DR3 or anti-TL1A component
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
232 participants (estimated)

Study arms

  • Experimental
    SL-325 high dose

    Drug: SL-325

  • Experimental
    SL-325 mid dose

    Drug: SL-325

  • Experimental
    SL-325 low dose

    Drug: SL-325

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants who achieve endoscopic response

    The proportion of participants who achieve endoscopic response, as defined by a ≥50% decrease in Simplified Endoscopic Score for Crohn's disease (SES-CD) from baseline.

    Time frame: Week 12

Secondary outcomes

  1. Proportion of participants who achieve clinical remission

    The proportion of participants who achieve clinical remission, as defined by a Crohn's Disease Activity Index \[CDAI\] score \< 150.

    Time frame: Week 12

  2. Incidence and severity of treatment-emergent adverse events

    Incidence and severity of treatment-emergent adverse events (TEAEs)

    Time frame: Week 12

  3. Number of participants who discontinue study intervention due to an TEAE

    Treatment-emergent adverse events (TEAEs) leading to discontinuation of study intervention

    Time frame: Week 12

07

Study locations

3 of 20 sites recruiting
  • Clinical Trial Site
    Little Rock, Arkansas 72205, United States
    Not yet recruiting
  • Clinical Trial Site
    Oxnard, California 93030, United States
    Not yet recruiting
  • Clinical Trial Site
    Temple City, California 91780, United States
    Not yet recruiting
  • Clinical Trial Site
    West Hills, California 91307, United States
    Not yet recruiting
  • Clinical Trial Site
    Inverness, Florida 34452, United States
    Not yet recruiting
  • Clinical Trial Site
    Kissimmee, Florida 34741, United States
    Recruiting
  • Clinical Trial Site
    Naples, Florida 34102, United States
    Not yet recruiting
  • Clinical Trial Site
    Orlando, Florida 32803, United States
    Not yet recruiting
  • Clinical Trial Site
    Tampa, Florida 33607, United States
    Not yet recruiting
  • Clinical Trial Site
    Kansas City, Kansas 66160, United States
    Not yet recruiting
  • Clinical Trial Site
    Houma, Louisiana 70360, United States
    Recruiting
  • Clinical Trial Site
    Marrero, Louisiana 70072, United States
    Not yet recruiting
  • Clinical Trial Site
    Glen Burnie, Maryland 21061, United States
    Not yet recruiting
  • Clinical Trial Site
    Boston, Massachusetts 02115, United States
    Not yet recruiting
  • Clinical Trial Site
    Liberty, Missouri 64068, United States
    Not yet recruiting
  • Clinical Trial Site
    St Louis, Missouri 63110, United States
    Not yet recruiting
  • Clinical Trial Site
    Maspeth, New York 11378, United States
    Not yet recruiting
  • Clinical Trial Site
    Cincinnati, Ohio 45219, United States
    Not yet recruiting
  • Clinical Trial Site
    Columbus, Ohio 43213, United States
    Not yet recruiting
  • Clinical Trial Site
    Nashville, Tennessee 37211, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement. Proposals will be reviewed based on scientific need, conflicts of interest, and regulatory approval status.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Jul 2028, 20 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 20 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2026
First posted
Aug 10, 2026
StartActual
Nov 9, 2026was Oct 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jun 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 3, 2026
Sites
20 sites added — first site in United States. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Clinical Trial Site · Houma, United StatesNot yet recruiting→Recruiting
  • Clinical Trial Site · Nashville, United StatesNot yet recruiting→Recruiting
Show 20 added (20 United States)
  • Clinical Trial Site · Little Rock, United States
  • Clinical Trial Site · Oxnard, United States
  • Clinical Trial Site · Temple City, United States
  • Clinical Trial Site · West Hills, United States
  • Clinical Trial Site · Inverness, United States
  • Clinical Trial Site · Kissimmee, United States
  • Clinical Trial Site · Naples, United States
  • Clinical Trial Site · Orlando, United States
  • Clinical Trial Site · Tampa, United States
  • Clinical Trial Site · Kansas City, United States
  • Clinical Trial Site · Houma, United States
  • Clinical Trial Site · Marrero, United States
  • Clinical Trial Site · Glen Burnie, United States
  • Clinical Trial Site · Boston, United States
  • Clinical Trial Site · Liberty, United States
  • Clinical Trial Site · St Louis, United States
  • Clinical Trial Site · Maspeth, United States
  • Clinical Trial Site · Cincinnati, United States
  • Clinical Trial Site · Columbus, United States
  • Clinical Trial Site · Nashville, United States
across 2 updates, Nov 3, 2026 – Nov 12, 2026
Start date
Oct 21, 2026→Nov 9, 2026 (actual)
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Clinical Trial Site · Houma, United StatesNot yet recruiting→Recruiting
    • Clinical Trial Site · Nashville, United StatesNot yet recruiting→Recruiting
    Start date Oct 21, 2026→Nov 9, 2026 (now actual)
    + 1 other change: verification date
  2. Nov 3, 2026
    Not yet recruiting→Recruiting
    20 sites added — first site in United States
    Show 20 added (20 United States)
    • Clinical Trial Site · Little Rock, United States
    • Clinical Trial Site · Oxnard, United States
    • Clinical Trial Site · Temple City, United States
    • Clinical Trial Site · West Hills, United States
    • Clinical Trial Site · Inverness, United States
    • Clinical Trial Site · Kissimmee, United States
    • Clinical Trial Site · Naples, United States
    • Clinical Trial Site · Orlando, United States
    • Clinical Trial Site · Tampa, United States
    • Clinical Trial Site · Kansas City, United States
    • Clinical Trial Site · Houma, United States
    • Clinical Trial Site · Marrero, United States
    • Clinical Trial Site · Glen Burnie, United States
    • Clinical Trial Site · Boston, United States
    • Clinical Trial Site · Liberty, United States
    • Clinical Trial Site · St Louis, United States
    • Clinical Trial Site · Maspeth, United States
    • Clinical Trial Site · Cincinnati, United States
    • Clinical Trial Site · Columbus, United States
    • Clinical Trial Site · Nashville, United States
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07753850
Lead sponsor
Shattuck Labs, Inc.
Responsible party
Sponsor
First posted
Aug 10, 2026
Start date
Nov 9, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jun 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Shattuck Medical Director
Contact
clinicaltrials@shattucklabs.com
919-864-2700

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 3-(2-(4-quinolin-3-yl)benzyl-1-oxoisoindolin-6-yl)-N-hydroxy-acrylamide

Start the discussion